Cargando…

Clinical quantification of the integrin αvβ6 by [(18)F]FB-A20FMDV2 positron emission tomography in healthy and fibrotic human lung (PETAL Study)

PURPOSE: The RGD-integrin, αvβ6, plays a role in the pathogenesis of pulmonary fibrosis through activation of transforming growth factor beta (TGFβ). This study sought to quantify expression of αvβ6 in the lungs of healthy humans and subjects with pulmonary fibrosis using the αvβ6-selective [(18)F]F...

Descripción completa

Detalles Bibliográficos
Autores principales: Lukey, Pauline T., Coello, Christopher, Gunn, Roger, Parker, Christine, Wilson, Frederick J., Saleem, Azeem, Garman, Nadia, Costa, Maria, Kendrick, Stuart, Onega, Mayca, Kang’ombe, Arthur R., Listanco, Allan, Davies, James, Ramada-Magalhaes, Joaquim, Moz, Sara, Fahy, William A., Maher, Toby M., Jenkins, Gisli, Passchier, Jan, Marshall, Richard P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7075837/
https://www.ncbi.nlm.nih.gov/pubmed/31814068
http://dx.doi.org/10.1007/s00259-019-04586-z
_version_ 1783507096892866560
author Lukey, Pauline T.
Coello, Christopher
Gunn, Roger
Parker, Christine
Wilson, Frederick J.
Saleem, Azeem
Garman, Nadia
Costa, Maria
Kendrick, Stuart
Onega, Mayca
Kang’ombe, Arthur R.
Listanco, Allan
Davies, James
Ramada-Magalhaes, Joaquim
Moz, Sara
Fahy, William A.
Maher, Toby M.
Jenkins, Gisli
Passchier, Jan
Marshall, Richard P.
author_facet Lukey, Pauline T.
Coello, Christopher
Gunn, Roger
Parker, Christine
Wilson, Frederick J.
Saleem, Azeem
Garman, Nadia
Costa, Maria
Kendrick, Stuart
Onega, Mayca
Kang’ombe, Arthur R.
Listanco, Allan
Davies, James
Ramada-Magalhaes, Joaquim
Moz, Sara
Fahy, William A.
Maher, Toby M.
Jenkins, Gisli
Passchier, Jan
Marshall, Richard P.
author_sort Lukey, Pauline T.
collection PubMed
description PURPOSE: The RGD-integrin, αvβ6, plays a role in the pathogenesis of pulmonary fibrosis through activation of transforming growth factor beta (TGFβ). This study sought to quantify expression of αvβ6 in the lungs of healthy humans and subjects with pulmonary fibrosis using the αvβ6-selective [(18)F]FB-A20FMDV2 PET ligand. METHODS: [(18)F]FB-A20FMDV2 PET/CT scans were performed in healthy subjects and those with fibrotic lung disease. Standard uptake values (SUV) and volume of distribution (V(T)) were used to quantify αvβ6 expression. In subjects with fibrotic lung disease, qualitative assessment of the relationship between αvβ6 expression and the distribution of fibrosis on high resolution computed tomography was conducted. RESULTS: A total of 15 participants (6 healthy, 7 with idiopathic pulmonary fibrosis (IPF) and 2 with connective tissue disease (CTD) associated PF) were enrolled. V(T) and SUV of [(18)F]FB-A20FMDV2 were increased in the lungs of subjects with pulmonary fibrosis (PF) compared with healthy subjects. Geometric mean V(T) (95% CI) was 0.88 (0.60, 1.29) mL/cm(3) for healthy subjects, and 1.40 (1.22, 1.61) mL/cm(3) for subjects with IPF; and SUV was 0.54 (0.36, 0.81) g/mL for healthy subjects and 1.03 (0.86, 1.22) g/mL for subjects with IPF. The IPF/healthy V(T) ratio (geometric mean, (95% CI of ratio)) was 1.59 (1.09, 2.32) (probability ratio > 1 = 0.988)) and the SUV ratio was 1.91 (1.27, 2.87) (probability ratio > 1 = 0.996). Increased uptake of [(18)F]FB-A20FMDV2 in PF was predominantly confined to fibrotic areas. [(18)F]FB-A20FMDV2 measurements were reproducible at an interval of 2 weeks. [(18)F]FB-A20FMDV2 was safe and well tolerated. CONCLUSIONS: Lung uptake of [(18)F]FB-A20FMDV2, a measure of expression of the integrin αvβ6, was markedly increased in subjects with PF compared with healthy subjects. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1007/s00259-019-04586-z) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-7075837
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Springer Berlin Heidelberg
record_format MEDLINE/PubMed
spelling pubmed-70758372020-03-23 Clinical quantification of the integrin αvβ6 by [(18)F]FB-A20FMDV2 positron emission tomography in healthy and fibrotic human lung (PETAL Study) Lukey, Pauline T. Coello, Christopher Gunn, Roger Parker, Christine Wilson, Frederick J. Saleem, Azeem Garman, Nadia Costa, Maria Kendrick, Stuart Onega, Mayca Kang’ombe, Arthur R. Listanco, Allan Davies, James Ramada-Magalhaes, Joaquim Moz, Sara Fahy, William A. Maher, Toby M. Jenkins, Gisli Passchier, Jan Marshall, Richard P. Eur J Nucl Med Mol Imaging Original Article PURPOSE: The RGD-integrin, αvβ6, plays a role in the pathogenesis of pulmonary fibrosis through activation of transforming growth factor beta (TGFβ). This study sought to quantify expression of αvβ6 in the lungs of healthy humans and subjects with pulmonary fibrosis using the αvβ6-selective [(18)F]FB-A20FMDV2 PET ligand. METHODS: [(18)F]FB-A20FMDV2 PET/CT scans were performed in healthy subjects and those with fibrotic lung disease. Standard uptake values (SUV) and volume of distribution (V(T)) were used to quantify αvβ6 expression. In subjects with fibrotic lung disease, qualitative assessment of the relationship between αvβ6 expression and the distribution of fibrosis on high resolution computed tomography was conducted. RESULTS: A total of 15 participants (6 healthy, 7 with idiopathic pulmonary fibrosis (IPF) and 2 with connective tissue disease (CTD) associated PF) were enrolled. V(T) and SUV of [(18)F]FB-A20FMDV2 were increased in the lungs of subjects with pulmonary fibrosis (PF) compared with healthy subjects. Geometric mean V(T) (95% CI) was 0.88 (0.60, 1.29) mL/cm(3) for healthy subjects, and 1.40 (1.22, 1.61) mL/cm(3) for subjects with IPF; and SUV was 0.54 (0.36, 0.81) g/mL for healthy subjects and 1.03 (0.86, 1.22) g/mL for subjects with IPF. The IPF/healthy V(T) ratio (geometric mean, (95% CI of ratio)) was 1.59 (1.09, 2.32) (probability ratio > 1 = 0.988)) and the SUV ratio was 1.91 (1.27, 2.87) (probability ratio > 1 = 0.996). Increased uptake of [(18)F]FB-A20FMDV2 in PF was predominantly confined to fibrotic areas. [(18)F]FB-A20FMDV2 measurements were reproducible at an interval of 2 weeks. [(18)F]FB-A20FMDV2 was safe and well tolerated. CONCLUSIONS: Lung uptake of [(18)F]FB-A20FMDV2, a measure of expression of the integrin αvβ6, was markedly increased in subjects with PF compared with healthy subjects. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1007/s00259-019-04586-z) contains supplementary material, which is available to authorized users. Springer Berlin Heidelberg 2019-12-09 2020 /pmc/articles/PMC7075837/ /pubmed/31814068 http://dx.doi.org/10.1007/s00259-019-04586-z Text en © The Author(s) 2019 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
spellingShingle Original Article
Lukey, Pauline T.
Coello, Christopher
Gunn, Roger
Parker, Christine
Wilson, Frederick J.
Saleem, Azeem
Garman, Nadia
Costa, Maria
Kendrick, Stuart
Onega, Mayca
Kang’ombe, Arthur R.
Listanco, Allan
Davies, James
Ramada-Magalhaes, Joaquim
Moz, Sara
Fahy, William A.
Maher, Toby M.
Jenkins, Gisli
Passchier, Jan
Marshall, Richard P.
Clinical quantification of the integrin αvβ6 by [(18)F]FB-A20FMDV2 positron emission tomography in healthy and fibrotic human lung (PETAL Study)
title Clinical quantification of the integrin αvβ6 by [(18)F]FB-A20FMDV2 positron emission tomography in healthy and fibrotic human lung (PETAL Study)
title_full Clinical quantification of the integrin αvβ6 by [(18)F]FB-A20FMDV2 positron emission tomography in healthy and fibrotic human lung (PETAL Study)
title_fullStr Clinical quantification of the integrin αvβ6 by [(18)F]FB-A20FMDV2 positron emission tomography in healthy and fibrotic human lung (PETAL Study)
title_full_unstemmed Clinical quantification of the integrin αvβ6 by [(18)F]FB-A20FMDV2 positron emission tomography in healthy and fibrotic human lung (PETAL Study)
title_short Clinical quantification of the integrin αvβ6 by [(18)F]FB-A20FMDV2 positron emission tomography in healthy and fibrotic human lung (PETAL Study)
title_sort clinical quantification of the integrin αvβ6 by [(18)f]fb-a20fmdv2 positron emission tomography in healthy and fibrotic human lung (petal study)
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7075837/
https://www.ncbi.nlm.nih.gov/pubmed/31814068
http://dx.doi.org/10.1007/s00259-019-04586-z
work_keys_str_mv AT lukeypaulinet clinicalquantificationoftheintegrinavb6by18ffba20fmdv2positronemissiontomographyinhealthyandfibrotichumanlungpetalstudy
AT coellochristopher clinicalquantificationoftheintegrinavb6by18ffba20fmdv2positronemissiontomographyinhealthyandfibrotichumanlungpetalstudy
AT gunnroger clinicalquantificationoftheintegrinavb6by18ffba20fmdv2positronemissiontomographyinhealthyandfibrotichumanlungpetalstudy
AT parkerchristine clinicalquantificationoftheintegrinavb6by18ffba20fmdv2positronemissiontomographyinhealthyandfibrotichumanlungpetalstudy
AT wilsonfrederickj clinicalquantificationoftheintegrinavb6by18ffba20fmdv2positronemissiontomographyinhealthyandfibrotichumanlungpetalstudy
AT saleemazeem clinicalquantificationoftheintegrinavb6by18ffba20fmdv2positronemissiontomographyinhealthyandfibrotichumanlungpetalstudy
AT garmannadia clinicalquantificationoftheintegrinavb6by18ffba20fmdv2positronemissiontomographyinhealthyandfibrotichumanlungpetalstudy
AT costamaria clinicalquantificationoftheintegrinavb6by18ffba20fmdv2positronemissiontomographyinhealthyandfibrotichumanlungpetalstudy
AT kendrickstuart clinicalquantificationoftheintegrinavb6by18ffba20fmdv2positronemissiontomographyinhealthyandfibrotichumanlungpetalstudy
AT onegamayca clinicalquantificationoftheintegrinavb6by18ffba20fmdv2positronemissiontomographyinhealthyandfibrotichumanlungpetalstudy
AT kangombearthurr clinicalquantificationoftheintegrinavb6by18ffba20fmdv2positronemissiontomographyinhealthyandfibrotichumanlungpetalstudy
AT listancoallan clinicalquantificationoftheintegrinavb6by18ffba20fmdv2positronemissiontomographyinhealthyandfibrotichumanlungpetalstudy
AT daviesjames clinicalquantificationoftheintegrinavb6by18ffba20fmdv2positronemissiontomographyinhealthyandfibrotichumanlungpetalstudy
AT ramadamagalhaesjoaquim clinicalquantificationoftheintegrinavb6by18ffba20fmdv2positronemissiontomographyinhealthyandfibrotichumanlungpetalstudy
AT mozsara clinicalquantificationoftheintegrinavb6by18ffba20fmdv2positronemissiontomographyinhealthyandfibrotichumanlungpetalstudy
AT fahywilliama clinicalquantificationoftheintegrinavb6by18ffba20fmdv2positronemissiontomographyinhealthyandfibrotichumanlungpetalstudy
AT mahertobym clinicalquantificationoftheintegrinavb6by18ffba20fmdv2positronemissiontomographyinhealthyandfibrotichumanlungpetalstudy
AT jenkinsgisli clinicalquantificationoftheintegrinavb6by18ffba20fmdv2positronemissiontomographyinhealthyandfibrotichumanlungpetalstudy
AT passchierjan clinicalquantificationoftheintegrinavb6by18ffba20fmdv2positronemissiontomographyinhealthyandfibrotichumanlungpetalstudy
AT marshallrichardp clinicalquantificationoftheintegrinavb6by18ffba20fmdv2positronemissiontomographyinhealthyandfibrotichumanlungpetalstudy